Soleno Therapeutics, Inc.

NASDAQ•SLNO

CEO: Dr. Anish Bhatnagar M.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2014-11-13

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

連絡先情報

203 Redwood Shores Parkway, Suite 500, Redwood City, CA, 94065, United States

650-213-8444

soleno.life

時価総額

$2.76B

PER (TTM)

28.7

22.8

配当利回り

52週高値

$90.32

52週安値

$29.43

52週レンジ

39%

順位51Top 71.3%

3.0

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$94.60M+0.00%

直近4四半期の推移

EPS

$0.60+0.00%

直近4四半期の推移

フリーCF

$25.94M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

First Year Profitability Achieved Net income $20.9M for 2025 after VYKAT XR approval in March; cash flow from operations $46.8M provided.

VYKAT XR Drives Revenue Product revenue reached $190.4M in 2025 following FDA approval; zero revenue reported in prior year.

R&D Spending Decreases Research and development expenses fell 48% to $40.6M in 2025 post-NDA submission; SG&A increased 25%.

Strong Cash Position Maintained Total assets grew to $563.8M by year-end 2025, supported by $215.7M in net stock sales proceeds.

リスク要因

Limited Commercialization History Financial results depend primarily on successful launch of sole product, VYKAT XR; sustained profitability uncertain.

Future Capital Needs Exist May require additional funding to support operations and scale sales; raising capital risks dilution or unfavorable terms.

Intellectual Property Challenges Patent litigation is prevalent; ability to maintain competitive advantage relies on strong, broad intellectual property protection.

Regulatory and Market Acceptance VYKAT XR must achieve broad market acceptance by payers and physicians; regulatory hurdles remain for international sales.

見通し

Continued VYKAT XR Launch Focus remains on successful launch, selling, and supporting VYKAT XR across the US market and distribution channels.

International Expansion Pursued Addressing EMA comments for EU Marketing Authorization Application; final commercialization strategy outside US pending.

Manage Growth and Operations Must continue improving managerial, operational, and financial systems to effectively manage rapid employee and operational growth.

同業比較

売上高 (TTM)

LEGN

$1.03B

+64.2%

APLS

$1.03B

+32.6%

RARE

$669.43M

+13.3%

粗利益率 (最新四半期)

QURE

93.9%

+33.9pp

APLS

78.9%

+11.7pp

RARE

77.9%

-2.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
PRAX	$6.98B	-29.2	-43.0%	0.1%
CELC	$6.34B	-38.9	-203.2%	41.9%
CNTA	$5.91B	-24.3	-60.4%	1.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

42.6%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月11日

EPS:$0.73

売上高:$93.78M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし